Advertisement

Digestive Diseases and Sciences

, Volume 63, Issue 4, pp 920–933 | Cite as

Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and Pancreatic Adenocarcinoma

  • Chiara Fania
  • Raffaele PezzilliEmail author
  • Gianvico Melzi d’Eril
  • Cecilia Gelfi
  • Alessandra Barassi
Original Article
  • 229 Downloads

Abstract

Background

There are a limited number of studies investigating the type of serum proteins capable of differentiating intraductal papillary mucinous neoplasms from benign or malignant diseases of the pancreas.

Aims

To select proteins able to differentiate intraductal papillary mucinous neoplasms from benign and malignant pancreatic disease using semiquantitative proteomics.

Methods

Serum samples were obtained from 74 patients (19 with type II intraductal papillary mucinous neoplasms, 8 with type I/III intraductal papillary mucinous neoplasms, 24 with chronic pancreatitis, 23 with pancreatic ductal adenocarcinomas) and 21 healthy subjects. Small proteins and peptides were assayed by matrix-assisted laser desorption/ionization for the detection of differentially abundant species possibly related to tumor onset. Serum pancreatic amylase, lipase, carcinoembryonic antigen and carbohydrate antigen 19-9 (CA 19-9) were also assayed.

Results

Twenty-six of 84 peaks detected were dysregulated (7 more abundant and 19 less abundant in the type II intraductal papillary mucinous neoplasms, p < 0.05). Of the differentially abundant peaks, 17 were commonly dysregulated (3 peaks more abundant and 13 less abundant in type II intraductal papillary mucinous neoplasms, and one at  m/z = 9961 at variance), indicating a protein fingerprint shared by types I/III and type II intraductal papillary mucinous neoplasms and pancreatic ductal adenocarcinomas.

Conclusions

These results suggest that our approach can be used to differentiate type II intraductal papillary mucinous neoplasms from type I/III neoplasms, and type II intraductal papillary mucinous neoplasms from pancreatic ductal adenocarcinomas.

Keywords

Biomarkers Neoplasms Cystic Pancreatic cancer Pancreatitis Matrix-assisted laser desorption/ionization 

Notes

Acknowledgments

The authors wish to thank Enrica Torretta of the Department of Biomedical Sciences for Health, University of Milan, Milan, Italy, for the revision of statistical analyses.

Funding

This work was funded by the Italian Ministry of University and Scientific Research (Grant No. FIRB RBRNO78MCT to C. Gelfi).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

10620_2018_4944_MOESM1_ESM.docx (34 kb)
Supplementary material 1 (DOCX 33 kb)

References

  1. 1.
    Buscarini E, Pezzilli R, Cannizzaro R, et al. Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms. Dig Liver Dis. 2014;46:479–493.CrossRefPubMedGoogle Scholar
  2. 2.
    Falconi M, Crippa S, Chari S, et al. Quality assessment of the guidelines on cystic neoplasms of the pancreas. Pancreatology. 2015;15:463–469.CrossRefPubMedGoogle Scholar
  3. 3.
    Capurso G, Boccia S, Salvia R, et al. Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a multicentre case–control study. Am J Gastroenterol. 2013;108:1003–1009.CrossRefPubMedGoogle Scholar
  4. 4.
    Pezzilli R, Melzi dʼEril G, Barassi A. Can serum pancreatic amylase and lipase levels be used as diagnostic markers to distinguish between patients with mucinous cystic lesions of the pancreas, chronic pancreatitis, and pancreatic ductal adenocarcinoma? Pancreas. 2016;45:1272–1275.CrossRefPubMedGoogle Scholar
  5. 5.
    Pezzilli R, Calculli L, Melzi d’Eril G, et al. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes. Hepatobiliary Pancreat Dis Int.. 2016;15:553–557.CrossRefPubMedGoogle Scholar
  6. 6.
    Rebours V, Le Faouder J, Laouirem S, et al. In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin-β4 as markers of malignant intraductal pancreatic mucinous neoplasms. Pancreatology. 2014;14:117–124.CrossRefPubMedGoogle Scholar
  7. 7.
    Corcos O, Couvelard A, Dargère D, et al. Proteomic assessment of markers for malignancy in the mucus of intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2012;41:169–174.CrossRefPubMedGoogle Scholar
  8. 8.
    Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–197.CrossRefPubMedGoogle Scholar
  9. 9.
    Fania C, Vasso M, Torretta E, et al. Setup for human sera MALDI profiling: the case of rhEPO treatment. Electrophoresis. 2011;32:1715–1727.CrossRefPubMedGoogle Scholar
  10. 10.
    Dudeja GV, Allen PJ. Premalignant cystic neoplasms of the pancreas. Semin Oncol. 2015;42:70–85.CrossRefPubMedGoogle Scholar
  11. 11.
    Ohtsuka T, Matsunaga T, Kimura H, et al. Role of pancreatic juice cytology in the preoperative management of intraductal papillary mucinous neoplasm of the pancreas in the era of international consensus guidelines 2012. World J Surg. 2014;38:2994–3001.CrossRefPubMedGoogle Scholar
  12. 12.
    Tamura K, Ohtsuka T, Ideno N, et al. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review. Ann Surg. 2014;259:360–368.CrossRefPubMedGoogle Scholar
  13. 13.
    Pezzilli R, Corsi MM, Barassi A, et al. The role of inflammation in patients with intraductal mucinous neoplasm of the pancreas and in those with pancreatic adenocarcinoma. Anticancer Res. 2010;30:3801–3805.PubMedGoogle Scholar
  14. 14.
    Salvia R, Malleo G, Marchegiani G, et al. Pancreatic resections for cystic neoplasms: from the surgeon’s presumption to the pathologist’s reality. Surgery. 2012;152:S135–S142.CrossRefPubMedGoogle Scholar
  15. 15.
    Crippa S, Pezzilli R, Bissolati M, et al. Active surveillance beyond 5 years is required for presumed branch-duct intraductal papillary mucinous neoplasms undergoing non-operative management. Am. J. Gastroenterol. 2017. (in press).Google Scholar
  16. 16.
    Pezzilli R, Fabbri D, Corsi MM, et al. Plasma concentrations of angiogenetic factors and angiogenetic inhibitors in patients with ductal pancreatic neoplasms. A pilot study. Clin Chem Lab Med. 2011;49:1047–1051.CrossRefPubMedGoogle Scholar
  17. 17.
    Velstra B, Vonk MA, Bonsing BA, et al. Serum peptide signatures for pancreatic cancer based on mass spectrometry: a comparison to CA19-9 levels and routine imaging techniques. J Cancer Res Clin Oncol. 2015;141:531–541.CrossRefPubMedGoogle Scholar
  18. 18.
    Xue A, Scarlett CJ, Chung L, et al. Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br J Cancer. 2010;103:391–400.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Potjer TP, Mertens BJ, Nicolardi S, et al. Application of a serum protein signature for pancreatic cancer to separate cases from controls in a pancreatic surveillance cohort. Transl Oncol.. 2016;9:242–247.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Cecconi D, Palmieri M, Donadelli M. Proteomics in pancreatic cancer research. Proteomics. 2011;11:816–828.CrossRefPubMedGoogle Scholar
  21. 21.
    Liu Z, Ma Y, Yang J, et al. Upregulated and downregulated proteins in hepatocellular carcinoma: a systematic review of proteomic profiling studies. OMICS. 2011;15:61–71.CrossRefPubMedGoogle Scholar
  22. 22.
    Zapico-Muñiz E, Farré-Viladrich A, Rico-Santana N, et al. Standardized peptidome profiling of human serum for the detection of pancreatic cancer. Pancreas. 2010;39:1293–1298.CrossRefPubMedGoogle Scholar
  23. 23.
    Gerdtsson AS, Malats N, Säll A, et al. A multicenter trial defining a serum protein signature associated with pancreatic ductal adenocarcinoma. Int J Proteom. 2015;2015:587250.CrossRefGoogle Scholar
  24. 24.
    Yoneyama T, Ohtsuki S, Honda K, et al. Identification of IGFBP2 and IGFBP3 as compensatory biomarkers for CA19-9 in early-stage pancreatic cancer using a combination of antibody-based and LC-MS/MS-based proteomics. PLoS ONE. 2016;11:e0161009.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kikkawa S, Sogawa K, Satoh M, et al. Identification of a novel biomarker for biliary tract cancer using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Int J Proteomics.. 2012;2012:108609.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Hart PA, Topazian M, Raimondo M, et al. Endoscopic pancreas fluid collection: methods and relevance for clinical care and translational science. Am J Gastroenterol. 2016;111:1258–1266.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Hortin GL, Sviridov D, Anderson NL. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem. 2008;54:1608–1616.CrossRefPubMedGoogle Scholar
  28. 28.
    Fania C, Sogno I, Vasso M, et al. A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification. Clin Chim Acta. 2015;439:42–49.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Clinical Proteomics UnitIRCCS Policlinico San DonatoSan Donato MilaneseItaly
  2. 2.Pancreas Unit, Department of Digestive SystemSant’Orsola-Malpighi HospitalBolognaItaly
  3. 3.Department of Health Sciences, San Paolo HospitalUniversity of MilanMilanItaly
  4. 4.Department of Biomedical Sciences for HealthUniversity of MilanMilanItaly

Personalised recommendations